6533b854fe1ef96bd12af669
RESEARCH PRODUCT
EARLY EFFICACY OF LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF VISCERAL LEISHMANIASIS
R. PempinelloRobert N. DavidsonPaolo FioreLucio Di MartinoGiovanna RossiLoredana TassoS. ScottiSalvatore MangravitiElio CastagnolaRaffaella GiacchinoLuigi GradoniAntonio Casciosubject
Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSeverity of Illness IndexGastroenterologyAmphotericin BAmphotericin BInternal medicineAnimalsHumansMedicineLeishmania infantumChildleishmaniasisDrug CarriersChemotherapybiologybusiness.industryPublic Health Environmental and Occupational HealthInfantAnemiaLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisItalyChild PreschoolLiposomesImmunologyLeishmaniasis VisceralFemaleParasitologyLiposomal amphotericinHemoglobinBone marrowLeishmania infantumbusinessmedicine.drugdescription
The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1996-05-01 |